Viloxazine in the treatmentof depressive neurosis: A controlled clinical study with doxepin and placebo

Journal Article

In a four-week, double-blind, clinical trial thirty-one patients with depressive neurosis were treated with viloxazine, doxepin, or placebo. There were no differences among the three groups in therapeutic effects. Many depressed out-patients improve on placebo. Viloxazine hydrochloride is one of a series of compounds developed to explore the central nervous system activity of the aryloxypropranololamine type of β-adreno-receptor antagonists. Initial clinical studies support the hypothesis that viloxazine has antidepressant properties in man.

Duke Authors

Cited Authors

  • McEvoy, JP; Sheridan, WF; Jr, WRCS

Published Date

  • 1980

Published In

  • British Journal of Psychiatry

Volume / Issue

  • 137 / 5

Start / End Page

  • 440 - 443